Jeffrey Quinn Lawyer

KALA BIO is a clinical-stage biopharmaceutical company specializing in the research and development of innovative therapies for rare and serious eye diseases. Guided by advanced science, they are focused on utilizing their proprietary MSC-S platform to develop regenerative healing therapies for ocular surface and retinal diseases, with the ultimate goal of preserving vision and changing lives.

With a strong commitment to improving vision and enhancing the lives of patients with rare, sight-threatening diseases, KALA BIO has already secured FDA approval for two ophthalmic products and continues to bring leadership and vision to the treatment of rare ophthalmic diseases through their innovative pipeline.

Generated from the website